News & Articles

The partnership enables LUMICKS to expand on the implementation of the z-Movi to new immunotherapeutic settings

Just leave a quick lab product review today for your chance to scoop one of our weekly $100 prizes

Watch this on-demand webinar to discover how pancreatic cancer-derived organoids can be used as a predictive tool for personalized medicine

The agreement allows First Genetics to bring its F-Genetics NGS system and in vitro diagnostic assays for reproductive health testing to Russian labs

Scientists are harnessing machine learning to make accurate measurements of breast cancer risk from a patient’s blood cells

Key topics to include COVID-19 and infectious diseases, diabetes, sepsis, cardiovascular disease and personalized medicine as the global clinical community comes together to make the future healthier

The Oncomine Dx target test aims to identify HER2 gene mutations in non-small lung cancer patients

New diagnostic test for MSI in solid tumors can inform physicians on immuno-oncology therapies and can guide treatment decisions for patients with Lynch-associated cancers

Your guide to choosing and implementing the best automated solutions for the clinical laboratory

To be in with a chance of winning a $500 Amazon Gift Card, simply cast your vote for the product that has made the most difference to your work

CellaVision integration with HORIBA’s HELO automated hematology platform enables unique two-way data flow and rapid results validation

Watch this on-demand webinar to learn about the applications for cell-based therapies and biologics using advanced high-throughput flow cytometry

The trial will study the use of ruxolitinib, a JAK inhibitor, to investigate its effect on reducing complications in deteriorating COVID-19 patients

People who recovered from COVID-19 shows that most individuals had generated antibodies that were intrinsically capable of neutralizing the SARS-CoV-2 virus

Register for this webinar to discover how pancreatic cancer-derived organoids can be used as a predictive tool for personalized medicine

Interim clinical study data shows ID NOW test performance of 94.7% sensitivity and 98.6% specificity

Assay will help guide treatment decisions in cases of non-small cell lung cancer

Register today to reserve a place at the Summit - it opens at 13:00 (BST) / 14:00 (CEST) / 08:00 (EDT) / 05:00 (PDT) on Monday, May 11

Collaboration will enable global development, manufacturing and distribution of the vaccine

The test will be available for qualified laboratories across the European Union by the end of May